TECTONIC THERAPEUTIC, INC. Additional Paid in Capital, Common Stock
TECTONIC THERAPEUTIC, INC. (TECX) had Additional Paid in Capital, Common Stock of $572.92 million as of 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2024-05-09
- 2024-03-31: Additional Paid in Capital, Common Stock $572.92M.
- 2023-12-31: Additional Paid in Capital, Common Stock $572.01M.
- 2023-09-30: Additional Paid in Capital, Common Stock $571.34M.
- 2023-06-30: Additional Paid in Capital, Common Stock $568.95M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2024-03-31 | $572.92M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $572.01M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $571.34M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $568.95M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $567.38M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $564.80M 10-K · filed 2024-03-14 |
| 2022-09-30 | $562.48M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $559.77M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $556.53M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $553.01M 10-K · filed 2023-03-23 |
| 2021-09-30 | $548.88M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $543.69M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $524.24M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $518.76M 10-K · filed 2022-03-17 |
| 2020-09-30 | $444.15M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $439.29M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $427.20M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $330.71M 10-K · filed 2021-03-18 |
| 2019-09-30 | $328.80M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $197.53M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $195.63M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $193.92M 10-K · filed 2020-03-16 |
| 2018-09-30 | $192.82M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $192.44M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $339.00K 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |